Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.34 |
| ▸ | PDE2A | O00408 | 5/20 | 0.34 |
| ▸ | IDO1 | P14902 | 7/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257309 | 0.78 | TP53 (0.39) | TP53 | |
| SCHEMBL257314 | 0.77 | TP53 (0.41) | TP53ADORA2AADORA1 | |
| SCHEMBL15020811 | 0.76 | TP53 (0.43) | IDO1TP53DYRK1A | |
| SCHEMBL257519 | 0.76 | MAPT (0.40) | TP53 | |
| SCHEMBL257700 | 0.76 | TP53 (0.34) | TP53 | |
| SCHEMBL21177370 | 0.71 | MAPT (0.45) | PDE10ATP53 | |
| SCHEMBL3490394 | 0.66 | HSD11B1 (0.40) | PDE10APDE2AIDO1HSD11B1DYRK1A | |
| SCHEMBL5412742 | 0.65 | HSP90AA1 (0.38) | PDE10APDE2AHSD11B1CD274DYRK1A | |
| SCHEMBL13945540 | 0.64 | KMT2A (0.41) | HSD11B1ADORA2AADORA1 | |
| SCHEMBL3491456 | 0.63 | HSD11B1 (0.42) | IDO1HSD11B1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| EP-2617723-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | Amorepacific Corporation (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | CNR1, CNR2, GPR18 | PDE10A 2768/4885PDE2A 3768/4885IDO1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.